contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carasent-ab-publ-year-end-report-january-december-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Carasent is an IT company. The company delivers products and services within communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security and backup solutions. Customers are mainly found within health and care, finance and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

redeye.se              Carasent (Q3 Review): In good shape for exciting 2026    Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha                             Carasent’s profitability turnaround continues on track.

Which intermediary? Contact them, and the matter should be resolved.

I have thousands of euros worth of Carasent ASA. It is no longer traded, so I am stuck with the shares. I thought there would have been an automatic exchange to Carasent AB… Is anyone else in the same situation? What should I do? How can I prevent this in the future?

redeye.se              Carasent: Back in Shape in 2024 – More to Come    Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised                              New Base Case SEK28 (NOK26.5)  We raise our Base Case to SEK28 (NOK26.5) due to a slightly lower WACC, raised mid- and long-term margin assumptions, and a larger confidence in the long-term TAM outlook in Sweden. Trading at about 3.6x sales 2025e, Carasent might not look that attractive, considering its soft LTM margins. However, we believe Carasent is set for substantial margin expansion over the next few years. With an R40 approaching 30-35% in 2026-2027, along with a very low churn and a non-cyclical end market, we believe Carasent’s valuation could approach R40 SaaS businesses that tend to be valued at 6-8x sales NTM (excluding Fortnox).

access.dnbcarnegie.com              DNB Carnegie Access:                               yes                   redeye.se              Carasent Q4: Slightly Softer than Expected    Redeye comments on Carasent’s Q4 report, showing slightly softer numbers than expected. However, our positive long-term view is unchanged.

Redeye expectations for the Q1 report on Feb 13th

Carnegielta commissioned research pre-Q4                   Inderes              Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -...    Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/carasent...

Carasent

Q4 2025 highlightsNet sales amounted to MSEK 93.6 (78.7), corresponding to a net sales growth of 19%.Organic growth amounted to 16%, while net acquisitions and divestments in the last twelve...

<div class="mfn-body"><p><strong>Q4 2025 highlights</strong></p><ul><li>Net sales amounted to MSEK 93.6 (78.7), corresponding to a net sales growth of 19%.</li><li>Organic growth amounted to 16%, while net acquisitions and divestments in the last twelve months accounted for MSEK 3.0 or 4 percentage points of growth.</li><li>EBITDA amounted to MSEK 23.8 (-8.7), corresponding to an EBITDA margin of 25% (-11%).</li><li>Adjusted EBITDA margin was 25% (15%).</li><li>Operating result, EBIT, amounted to MSEK 7.8 (-24.1).</li><li>EBITDAC margin was 16% (-21%)</li><li>Cash flow from operating activities amounted to MSEK 20.6 (16.3).</li><li>Profit after tax amounted to MSEK 29.1 (-24.2).</li><li>Earnings per share, before and after dilution, amounted to SEK 0.42 (-0.34).</li></ul><p><strong>FY 2025 highlights</strong></p><ul><li>Net sales amounted to MSEK 343.8 (275.3), corresponding to a net sales growth of 25%. </li><li>Organic growth amounted to 14%, while net acquisitions and divestments in the last twelve months accounted for MSEK 31.1 or 11 percentage points of growth.</li><li>EBITDA amounted to MSEK 73.3 (11.6), corresponding to an EBITDA margin of 21% (4%). </li><li>Adjusted EBITDA margin was 21% (15%). </li><li>Operating result, EBIT amounted to MSEK 9.4 (-54.5). </li><li>EBITDAC margin was 10% (-11%)</li><li>Cash flow from operating activities amounted to MSEK 40.4 (37.7). </li><li>Profit after tax amounted to MSEK 34.8 (-42.3).</li><li>Earnings per share, before and after dilution, amounted to SEK 0.5 (-0.59).</li></ul><p>The results will be presented as a webcast at 8:00 CET today. If you wish to participate via webcast please use the link below.<br><a rel="noopener" href="https://events.inderes.com/carasent/q4-report-2025">https://events.inderes.com/carasent/q4-report-2025</a><br><br>For further details please contact:<br>Daniel Öhman, CEO Tel: +46 70-855 37 07, or<br>Svein Martin Bjørnstad, CFO Tel: +47 979 69 493</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Carasent is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-12 07:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/94d49000-6655-4ec1-a5dd-f02adac31049/carasent-q42025-en.pdf" class="mfn-primary">Carasent Q42025 En</a><br><a rel="noopener" href="https://storage.mfn.se/e4ed78a0-524f-4675-aaaa-34e378ab5b25/carasent-q4-2025-presentation.pdf">Carasent Q4 2025 Presentation</a></p></div>